INTERVENTION 1:	Intervention	0
Paclitaxel With Trastuzumab and Lapatinib	Intervention	1
paclitaxel	CHEBI:45863	0-10
lapatinib	CHEBI:49603	32-41
Paclitaxel (T) at 175 mg/m2 q 2 weeks x 4 with filgrastim/pegfilgrastim + trastuzumab (H) + daily oral lapatinib (L), followed by trastuzumab q 3 weeks x 15 doses + daily oral lapatinib (HL). Pegfilgrastim 6mg will be given subcutaneously (SQ) on day # 2 of each paclitaxel administration. Filgrastim may be used in lieu of pegfilgrastim at physician's discretion. Trastuzumab will be administered weekly (4 mg/kg bolus followed by 2 mg/kg weekly) starting with paclitaxel treatment cycle # 1. After 4 cycles of paclitaxel, pts will receive trastuzumab on a q 3 weeks x 15 doses (to complete about one year). The q 3 week trastuzumab may be started from 1-3 weeks after the last dose of paclitaxel. A total of 15 infusions of trastuzumab will be given q 3 weeks after the completion of paclitaxel during the HL phase. Lapatinib will be given orally at 1000 mg daily, starting with paclitaxel during the THL phase & continued for the remaining year during the HL phase for about a year.	Intervention	2
paclitaxel	CHEBI:45863	0-10
paclitaxel	CHEBI:45863	263-273
paclitaxel	CHEBI:45863	462-472
paclitaxel	CHEBI:45863	512-522
paclitaxel	CHEBI:45863	687-697
paclitaxel	CHEBI:45863	786-796
paclitaxel	CHEBI:45863	881-891
t	CHEBI:36371,BAO:0001260	5-6
t	CHEBI:36371,BAO:0001260	12-13
t	CHEBI:36371,BAO:0001260	16-17
t	CHEBI:36371,BAO:0001260	44-45
t	CHEBI:36371,BAO:0001260	54-55
t	CHEBI:36371,BAO:0001260	68-69
t	CHEBI:36371,BAO:0001260	74-75
t	CHEBI:36371,BAO:0001260	78-79
t	CHEBI:36371,BAO:0001260	107-108
t	CHEBI:36371,BAO:0001260	130-131
t	CHEBI:36371,BAO:0001260	134-135
t	CHEBI:36371,BAO:0001260	180-181
t	CHEBI:36371,BAO:0001260	202-203
t	CHEBI:36371,BAO:0001260	229-230
t	CHEBI:36371,BAO:0001260	268-269
t	CHEBI:36371,BAO:0001260	281-282
t	CHEBI:36371,BAO:0001260	284-285
t	CHEBI:36371,BAO:0001260	297-298
t	CHEBI:36371,BAO:0001260	334-335
t	CHEBI:36371,BAO:0001260	339-340
t	CHEBI:36371,BAO:0001260	359-360
t	CHEBI:36371,BAO:0001260	365-366
t	CHEBI:36371,BAO:0001260	369-370
t	CHEBI:36371,BAO:0001260	392-393
t	CHEBI:36371,BAO:0001260	449-450
t	CHEBI:36371,BAO:0001260	452-453
t	CHEBI:36371,BAO:0001260	459-460
t	CHEBI:36371,BAO:0001260	467-468
t	CHEBI:36371,BAO:0001260	473-474
t	CHEBI:36371,BAO:0001260	477-478
t	CHEBI:36371,BAO:0001260	481-482
t	CHEBI:36371,BAO:0001260	496-497
t	CHEBI:36371,BAO:0001260	517-518
t	CHEBI:36371,BAO:0001260	525-526
t	CHEBI:36371,BAO:0001260	541-542
t	CHEBI:36371,BAO:0001260	545-546
t	CHEBI:36371,BAO:0001260	580-581
t	CHEBI:36371,BAO:0001260	589-590
t	CHEBI:36371,BAO:0001260	596-597
t	CHEBI:36371,BAO:0001260	609-610
t	CHEBI:36371,BAO:0001260	622-623
t	CHEBI:36371,BAO:0001260	626-627
t	CHEBI:36371,BAO:0001260	642-643
t	CHEBI:36371,BAO:0001260	645-646
t	CHEBI:36371,BAO:0001260	666-667
t	CHEBI:36371,BAO:0001260	670-671
t	CHEBI:36371,BAO:0001260	677-678
t	CHEBI:36371,BAO:0001260	692-693
t	CHEBI:36371,BAO:0001260	701-702
t	CHEBI:36371,BAO:0001260	703-704
t	CHEBI:36371,BAO:0001260	726-727
t	CHEBI:36371,BAO:0001260	730-731
t	CHEBI:36371,BAO:0001260	764-765
t	CHEBI:36371,BAO:0001260	768-769
t	CHEBI:36371,BAO:0001260	778-779
t	CHEBI:36371,BAO:0001260	791-792
t	CHEBI:36371,BAO:0001260	804-805
t	CHEBI:36371,BAO:0001260	822-823
t	CHEBI:36371,BAO:0001260	850-851
t	CHEBI:36371,BAO:0001260	868-869
t	CHEBI:36371,BAO:0001260	871-872
t	CHEBI:36371,BAO:0001260	878-879
t	CHEBI:36371,BAO:0001260	886-887
t	CHEBI:36371,BAO:0001260	899-900
t	CHEBI:36371,BAO:0001260	903-904
t	CHEBI:36371,BAO:0001260	918-919
t	CHEBI:36371,BAO:0001260	929-930
t	CHEBI:36371,BAO:0001260	955-956
t	CHEBI:36371,BAO:0001260	976-977
x	LABO:0000148	7-8
x	LABO:0000148	38-39
x	LABO:0000148	152-153
x	LABO:0000148	270-271
x	LABO:0000148	469-470
x	LABO:0000148	519-520
x	LABO:0000148	568-569
x	LABO:0000148	694-695
x	LABO:0000148	793-794
x	LABO:0000148	888-889
lapatinib	CHEBI:49603	103-112
lapatinib	CHEBI:49603	176-185
lapatinib	CHEBI:49603	818-827
day	UO:0000033	247-250
year	UO:0000036	602-606
year	UO:0000036	943-947
year	UO:0000036	980-984
week	UO:0000034	32-36
week	UO:0000034	146-150
week	UO:0000034	398-402
week	UO:0000034	440-444
week	UO:0000034	562-566
week	UO:0000034	617-621
week	UO:0000034	658-662
week	UO:0000034	756-760
Paclitaxel	Intervention	3
paclitaxel	CHEBI:45863	0-10
Inclusion Criteria:	Eligibility	0
Patients must have histologically confirmed adenocarcinoma with HER2/neu immunohistochemistry 3+ or FISH-amplified breast cancer with a ratio of  2.0	Eligibility	1
adenocarcinoma	DOID:299	44-58
immunohistochemistry	BAO:0000415	73-93
breast cancer	DOID:1612	115-128
ratio	UO:0000190	136-141
Tumor size of  3 cm and node-negative disease. Nodes with single cells or tumor clusters < 0.2 mm by H&E or IHC are considered node-negative. Patients with micrometastasis (nodes with tumor clusters between 0.02 and 0.2 cm) are allowed. Further axillary dissection will be determined by the patient's surgeon as per standard of care.	Eligibility	2
size	PATO:0000117	6-10
disease	DOID:4,OGMS:0000031	38-45
patient	HADO:0000008,OAE:0001817	142-149
patient	HADO:0000008,OAE:0001817	291-298
Patients must be 18 years of age.	Eligibility	3
age	PATO:0000011	29-32
Patients must have an ECOG performance status of 0 or 1.	Eligibility	4
Treatment should be started within 90 days of the final surgical procedure for breast cancer.	Eligibility	5
breast cancer	DOID:1612	79-92
Patients may have bilateral synchronous breast tumors. Patients may have received hormonal therapy for the purpose of chemoprevention but must be willing to discontinue prior to enrollment and while participating in this trial.	Eligibility	6
bilateral	HP:0012832	18-27
breast	UBERON:0000310	40-46
If patients have peripheral neuropathy, it must be  grade 1.	Eligibility	7
peripheral neuropathy	HP:0009830,DOID:870	17-38
Patients must be willing to discontinue sex hormonal therapy e.g., birth control pills, ovarian hormonal replacement therapy, etc., prior to enrollment. Women of childbearing potential must be willing to consent to using effective contraception while on treatment and for a reasonable period thereafter.	Eligibility	8
Hematologic parameters: absolute neutrophil count (ANC) 1500/μL and platelet count 100,000/μL.	Eligibility	9
platelet count	CMO:0000029	68-82
Non-hematologic parameters: total bilirubin must be  1.5 X institutional upper limit of normal (ULN), transaminases (SGOT or SGPT)  3.0 x ULN.	Eligibility	10
x	LABO:0000148	57-58
x	LABO:0000148	136-137
Negative HCG pregnancy test for premenopausal women of reproductive capacity and for women less than 12 months after the menopause. LVEF by ECHO (with strain if possible) with LVEF of  50%. If an ECHO cannot be done, a MUGA may be performed.	Eligibility	11
menopause	GO:0042697	121-130
Patients must give written, informed consent indicating their understanding of and willingness to participate in the study.	Eligibility	12
Exclusion Criteria:	Eligibility	13
Patients with stage IV breast cancer or undergoing chemotherapy, radiation therapy, immunotherapy, or biotherapy for current breast cancer.	Eligibility	14
breast cancer	DOID:1612	23-36
breast cancer	DOID:1612	125-138
Pregnant or breastfeeding patients.	Eligibility	15
Patients with a concurrently active second malignancy, other than adequately treated non-melanoma skin cancers or in situ cervical cancer.	Eligibility	16
active	PATO:0002354	29-35
second	UO:0000010	36-42
cervical cancer	DOID:4362	122-137
Patients with unstable angina, congestive heart failure, or with a history of a myocardial infarction within 12 months. Patients with high-risk uncontrolled arrhythmias (ventricular tachycardia, high-grade AV block, supraventricular arrhythmias which are not adequately rate-controlled). Patients are excluded if they have grade 3 QT prolongation (Appendix F) (>500 ms) or require drugs that may prolong the QT.	Eligibility	17
congestive heart failure	HP:0001635,DOID:6000	31-55
history	BFO:0000182	67-74
myocardial infarction	HP:0001658,DOID:5844	80-101
ventricular tachycardia	HP:0004756	170-193
excluded	HP:0040285	301-309
f	UO:0000195	48-49
f	UO:0000195	76-77
f	UO:0000195	93-94
f	UO:0000195	311-312
f	UO:0000195	357-358
Subjects who have current active hepatic (including hepatitis B or C) or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones).	Eligibility	18
active	PATO:0002354	26-32
hepatitis b	DOID:2043	52-63
disease	DOID:4,OGMS:0000031	81-88
syndrome	DOID:225	132-140
Patients with active, unresolved infections.	Eligibility	19
active	PATO:0002354	14-20
Patients with a sensitivity to E. coli derived proteins.	Eligibility	20
Outcome Measurement:	Results	0
Number of Participants Who Are Able to Complete THL (Paclitaxel, Trastuzumab, and Lapatinib) Without a Dose Delay or Reduction, Grade 3 or Greater QTc Prolongation	Results	1
paclitaxel	CHEBI:45863	53-63
lapatinib	CHEBI:49603	82-91
The primary objective of this trial is to determine the feasibility of this regimen in patients with node-negative HER-2/neu overexpressed /amplified breast cancer with a tumor size of < 3 cm. The regimen is considered feasible if patients are able to complete the paclitaxel, trastuzumab, and lapatinib (THL) portion of the regimen without a dose delay or reduction or grade 3 or greater QTc prolongation.	Results	2
breast cancer	DOID:1612	150-163
size	PATO:0000117	177-181
paclitaxel	CHEBI:45863	265-275
lapatinib	CHEBI:49603	294-303
Time frame: 1 year	Results	3
time	PATO:0000165	0-4
year	UO:0000036	14-18
Results 1:	Results	4
Arm/Group Title: Paclitaxel With Trastuzumab and Lapatinib	Results	5
paclitaxel	CHEBI:45863	17-27
lapatinib	CHEBI:49603	49-58
Arm/Group Description: Paclitaxel (T) at 175 mg/m2 q 2 weeks x 4 with filgrastim/pegfilgrastim + trastuzumab (H) + daily oral lapatinib (L), followed by trastuzumab q 3 weeks x 15 doses + daily oral lapatinib (HL). Pegfilgrastim 6mg will be given subcutaneously (SQ) on day # 2 of each paclitaxel administration. Filgrastim may be used in lieu of pegfilgrastim at physician's discretion. Trastuzumab will be administered weekly (4 mg/kg bolus followed by 2 mg/kg weekly) starting with paclitaxel treatment cycle # 1. After 4 cycles of paclitaxel, pts will receive trastuzumab on a q 3 weeks x 15 doses (to complete about one year). The q 3 week trastuzumab may be started from 1-3 weeks after the last dose of paclitaxel. A total of 15 infusions of trastuzumab will be given q 3 weeks after the completion of paclitaxel during the HL phase. Lapatinib will be given orally at 1000 mg daily, starting with paclitaxel during the THL phase & continued for the remaining year during the HL phase for about a year.	Results	6
paclitaxel	CHEBI:45863	23-33
paclitaxel	CHEBI:45863	286-296
paclitaxel	CHEBI:45863	485-495
paclitaxel	CHEBI:45863	535-545
paclitaxel	CHEBI:45863	710-720
paclitaxel	CHEBI:45863	809-819
paclitaxel	CHEBI:45863	904-914
t	CHEBI:36371,BAO:0001260	17-18
t	CHEBI:36371,BAO:0001260	28-29
t	CHEBI:36371,BAO:0001260	35-36
t	CHEBI:36371,BAO:0001260	39-40
t	CHEBI:36371,BAO:0001260	67-68
t	CHEBI:36371,BAO:0001260	77-78
t	CHEBI:36371,BAO:0001260	91-92
t	CHEBI:36371,BAO:0001260	97-98
t	CHEBI:36371,BAO:0001260	101-102
t	CHEBI:36371,BAO:0001260	130-131
t	CHEBI:36371,BAO:0001260	153-154
t	CHEBI:36371,BAO:0001260	157-158
t	CHEBI:36371,BAO:0001260	203-204
t	CHEBI:36371,BAO:0001260	225-226
t	CHEBI:36371,BAO:0001260	252-253
t	CHEBI:36371,BAO:0001260	291-292
t	CHEBI:36371,BAO:0001260	304-305
t	CHEBI:36371,BAO:0001260	307-308
t	CHEBI:36371,BAO:0001260	320-321
t	CHEBI:36371,BAO:0001260	357-358
t	CHEBI:36371,BAO:0001260	362-363
t	CHEBI:36371,BAO:0001260	382-383
t	CHEBI:36371,BAO:0001260	388-389
t	CHEBI:36371,BAO:0001260	392-393
t	CHEBI:36371,BAO:0001260	415-416
t	CHEBI:36371,BAO:0001260	472-473
t	CHEBI:36371,BAO:0001260	475-476
t	CHEBI:36371,BAO:0001260	482-483
t	CHEBI:36371,BAO:0001260	490-491
t	CHEBI:36371,BAO:0001260	496-497
t	CHEBI:36371,BAO:0001260	500-501
t	CHEBI:36371,BAO:0001260	504-505
t	CHEBI:36371,BAO:0001260	519-520
t	CHEBI:36371,BAO:0001260	540-541
t	CHEBI:36371,BAO:0001260	548-549
t	CHEBI:36371,BAO:0001260	564-565
t	CHEBI:36371,BAO:0001260	568-569
t	CHEBI:36371,BAO:0001260	603-604
t	CHEBI:36371,BAO:0001260	612-613
t	CHEBI:36371,BAO:0001260	619-620
t	CHEBI:36371,BAO:0001260	632-633
t	CHEBI:36371,BAO:0001260	645-646
t	CHEBI:36371,BAO:0001260	649-650
t	CHEBI:36371,BAO:0001260	665-666
t	CHEBI:36371,BAO:0001260	668-669
t	CHEBI:36371,BAO:0001260	689-690
t	CHEBI:36371,BAO:0001260	693-694
t	CHEBI:36371,BAO:0001260	700-701
t	CHEBI:36371,BAO:0001260	715-716
t	CHEBI:36371,BAO:0001260	724-725
t	CHEBI:36371,BAO:0001260	726-727
t	CHEBI:36371,BAO:0001260	749-750
t	CHEBI:36371,BAO:0001260	753-754
t	CHEBI:36371,BAO:0001260	787-788
t	CHEBI:36371,BAO:0001260	791-792
t	CHEBI:36371,BAO:0001260	801-802
t	CHEBI:36371,BAO:0001260	814-815
t	CHEBI:36371,BAO:0001260	827-828
t	CHEBI:36371,BAO:0001260	845-846
t	CHEBI:36371,BAO:0001260	873-874
t	CHEBI:36371,BAO:0001260	891-892
t	CHEBI:36371,BAO:0001260	894-895
t	CHEBI:36371,BAO:0001260	901-902
t	CHEBI:36371,BAO:0001260	909-910
t	CHEBI:36371,BAO:0001260	922-923
t	CHEBI:36371,BAO:0001260	926-927
t	CHEBI:36371,BAO:0001260	941-942
t	CHEBI:36371,BAO:0001260	952-953
t	CHEBI:36371,BAO:0001260	978-979
t	CHEBI:36371,BAO:0001260	999-1000
x	LABO:0000148	30-31
x	LABO:0000148	61-62
x	LABO:0000148	175-176
x	LABO:0000148	293-294
x	LABO:0000148	492-493
x	LABO:0000148	542-543
x	LABO:0000148	591-592
x	LABO:0000148	717-718
x	LABO:0000148	816-817
x	LABO:0000148	911-912
lapatinib	CHEBI:49603	126-135
lapatinib	CHEBI:49603	199-208
lapatinib	CHEBI:49603	841-850
day	UO:0000033	270-273
year	UO:0000036	625-629
year	UO:0000036	966-970
year	UO:0000036	1003-1007
week	UO:0000034	55-59
week	UO:0000034	169-173
week	UO:0000034	421-425
week	UO:0000034	463-467
week	UO:0000034	585-589
week	UO:0000034	640-644
week	UO:0000034	681-685
week	UO:0000034	779-783
Paclitaxel	Results	7
paclitaxel	CHEBI:45863	0-10
Overall Number of Participants Analyzed: 20	Results	8
Measure Type: Count of Participants	Results	9
Unit of Measure: Participants  Did not complete treatment: 16  80.0%	Results	10
Successfully completed treatment: 4  20.0%	Results	11
Adverse Events 1:	Adverse Events	0
Total: 4/20 (20.00%)	Adverse Events	1
Fatigue  1/20 (5.00%)	Adverse Events	2
fatigue	HP:0012378	0-7
Fever  1/20 (5.00%)	Adverse Events	3
fever	HP:0001945	0-5
Hepatic failure  1/20 (5.00%)	Adverse Events	4
hepatic failure	HP:0001399	0-15
Breast infection  1/20 (5.00%)	Adverse Events	5
breast	UBERON:0000310	0-6
Alanine aminotransferase increased  1/20 (5.00%)	Adverse Events	6
alanine	CHEBI:16449	0-7
Aspartate aminotransferase increased  1/20 (5.00%)	Adverse Events	7
aspartate	CHEBI:29995	0-9
Creatinine increased  1/20 (5.00%)	Adverse Events	8
creatinine	CHEBI:16737	0-10
Dehydration  1/20 (5.00%)	Adverse Events	9
dehydration	HP:0001944	0-11
Transient ischemic attacks  1/20 (5.00%)	Adverse Events	10
transient	HP:0025153	0-9
Hypertension  1/20 (5.00%)	Adverse Events	11
hypertension	HP:0000822,DOID:10763	0-12
